Stryker (SYK) Expected to Announce Earnings on Thursday

Stryker (NYSE:SYK) is projected to release its Q3 2025 results after the market closes on Thursday, October 30th. Analysts expect Stryker to post earnings of $3.14 per share and revenue of $6.0434 billion for the quarter. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS.Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 4:30 PM ET.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.81 earnings per share. On average, analysts expect Stryker to post $13 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Stryker Stock Performance

Shares of SYK stock opened at $376.11 on Wednesday. The stock has a market cap of $143.79 billion, a P/E ratio of 49.82, a P/E/G ratio of 2.76 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The company has a fifty day moving average price of $379.59 and a two-hundred day moving average price of $380.49. Stryker has a one year low of $329.16 and a one year high of $406.19.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker’s dividend payout ratio (DPR) is currently 44.50%.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider directly owned 12,511 shares in the company, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 5.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Stryker

A number of hedge funds have recently bought and sold shares of the business. Corient Private Wealth LLC increased its position in Stryker by 104.4% during the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after acquiring an additional 1,146,998 shares during the period. California State Teachers Retirement System increased its position in Stryker by 1.4% during the second quarter. California State Teachers Retirement System now owns 546,066 shares of the medical technology company’s stock worth $216,040,000 after acquiring an additional 7,671 shares during the period. CANADA LIFE ASSURANCE Co increased its position in Stryker by 4.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 373,444 shares of the medical technology company’s stock worth $147,903,000 after acquiring an additional 14,280 shares during the period. Canada Pension Plan Investment Board increased its position in Stryker by 132.8% during the second quarter. Canada Pension Plan Investment Board now owns 355,126 shares of the medical technology company’s stock worth $140,498,000 after acquiring an additional 202,555 shares during the period. Finally, Adage Capital Partners GP L.L.C. increased its position in Stryker by 75.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 235,484 shares of the medical technology company’s stock worth $93,165,000 after acquiring an additional 101,137 shares during the period. 77.09% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. UBS Group set a $408.00 price target on shares of Stryker in a research note on Monday, October 13th. Barclays increased their price target on shares of Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. BTIG Research increased their price objective on shares of Stryker from $407.00 to $408.00 and gave the company a “buy” rating in a research report on Monday, October 13th. Finally, Truist Financial dropped their price objective on shares of Stryker from $415.00 to $407.00 and set a “hold” rating on the stock in a research report on Wednesday, October 15th. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $432.24.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.